Literature DB >> 21041502

Activities of NXL104 combinations with ceftazidime and aztreonam against carbapenemase-Producing Enterobacteriaceae.

David M Livermore1, Shazad Mushtaq, Marina Warner, Jiancheng Zhang, Sunil Maharjan, Michel Doumith, Neil Woodford.   

Abstract

Combinations of NXL104 with ceftazidime and aztreonam were tested against carbapenem-resistant members of the Enterobacteriaceae. Ceftazidime-NXL104 was active against strains with the OXA-48 enzyme or with combinations of impermeability and an extended-spectrum β-lactamase (ESBL) or AmpC enzyme and also against most Klebsiella spp. with the KPC enzyme, but metallo-β-lactamase producers were resistant. Aztreonam-NXL104 was active against all carbapenemase producers at 4 and 4 μg/ml, including those with metallo-β-lactamases.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 21041502      PMCID： PMC3019623          DOI： 10.1128/AAC.00756-10

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  21 in total

1.  Wide geographic spread of diverse acquired AmpC beta-lactamases among Escherichia coli and Klebsiella spp. in the UK and Ireland.

Authors:  Neil Woodford; Suganya Reddy; Elizabeth J Fagan; Robert L R Hill; Katie L Hopkins; Mary E Kaufmann; James Kistler; Marie-France I Palepou; Rachel Pike; M Elaina Ward; John Cheesbrough; David M Livermore
Journal:  J Antimicrob Chemother       Date:  2006-11-16       Impact factor: 5.790

Review 2.  The beta-lactamase threat in Enterobacteriaceae, Pseudomonas and Acinetobacter.

Authors:  David M Livermore; Neil Woodford
Journal:  Trends Microbiol       Date:  2006-07-31       Impact factor: 17.079

3.  Multiplex PCR for rapid detection of genes encoding acquired metallo-beta-lactamases.

Authors:  Matthew J Ellington; James Kistler; David M Livermore; Neil Woodford
Journal:  J Antimicrob Chemother       Date:  2006-12-21       Impact factor: 5.790

Review 4.  Carbapenemases: the versatile beta-lactamases.

Authors:  Anne Marie Queenan; Karen Bush
Journal:  Clin Microbiol Rev       Date:  2007-07       Impact factor: 26.132

5.  Ertapenem resistance among Klebsiella and Enterobacter submitted in the UK to a reference laboratory.

Authors:  Neil Woodford; John W T Dallow; Robert L R Hill; Marie-France I Palepou; Rachel Pike; M Elaina Ward; Marina Warner; David M Livermore
Journal:  Int J Antimicrob Agents       Date:  2007-02-12       Impact factor: 5.283

6.  Community and hospital spread of Escherichia coli producing CTX-M extended-spectrum beta-lactamases in the UK.

Authors:  N Woodford; M E Ward; M E Kaufmann; J Turton; E J Fagan; D James; A P Johnson; R Pike; M Warner; T Cheasty; A Pearson; S Harry; J B Leach; A Loughrey; J A Lowes; R E Warren; D M Livermore
Journal:  J Antimicrob Chemother       Date:  2004-09-03       Impact factor: 5.790

7.  NXL104 combinations versus Enterobacteriaceae with CTX-M extended-spectrum beta-lactamases and carbapenemases.

Authors:  David M Livermore; Shazad Mushtaq; Marina Warner; Christine Miossec; Neil Woodford
Journal:  J Antimicrob Chemother       Date:  2008-08-09       Impact factor: 5.790

Review 8.  High rates of metallo-beta-lactamase-producing Klebsiella pneumoniae in Greece--a review of the current evidence.

Authors:  A Vatopoulos
Journal:  Euro Surveill       Date:  2008-01-24

Review 9.  Novel beta-lactam antibiotics and inhibitor combinations.

Authors:  Matteo Bassetti; Elda Righi; Claudio Viscoli
Journal:  Expert Opin Investig Drugs       Date:  2008-03       Impact factor: 6.206

10.  Comparative activities of doripenem versus isolates, mutants, and transconjugants of Enterobacteriaceae and Acinetobacter spp. with characterized beta-lactamases.

Authors:  Shazad Mushtaq; Yigong Ge; David M Livermore
Journal:  Antimicrob Agents Chemother       Date:  2004-04       Impact factor: 5.191
View more
  99 in total

1.  In Vitro Activities of Ceftazidime-Avibactam, Aztreonam-Avibactam, and a Panel of Older and Contemporary Antimicrobial Agents against Carbapenemase-Producing Gram-Negative Bacilli.

Authors:  Shawn Vasoo; Scott A Cunningham; Nicolynn C Cole; Peggy C Kohner; Sanjay R Menon; Kevin M Krause; Kelly A Harris; Partha P De; Tse Hsien Koh; Robin Patel
Journal:  Antimicrob Agents Chemother       Date:  2015-09-21       Impact factor: 5.191

2.  An Automated Miniaturized Method to Perform and Analyze Antimicrobial Drug Synergy Assays.

Authors:  Peter Chase; Imarhia Enogieru; Franck Madoux; Eric Bishop; Jacob Beer; Louis Scampavia; Timothy Spicer
Journal:  Assay Drug Dev Technol       Date:  2015-12-15       Impact factor: 1.738

3.  Activities of ceftazidime and avibactam against β-lactamase-producing Enterobacteriaceae in a hollow-fiber pharmacodynamic model.

Authors:  Ken Coleman; Premavathy Levasseur; Anne-Marie Girard; Monica Borgonovi; Christine Miossec; Henri Merdjan; George Drusano; David Shlaes; Wright W Nichols
Journal:  Antimicrob Agents Chemother       Date:  2014-03-31       Impact factor: 5.191

4.  In Vitro Activity of Aztreonam-Avibactam against Enterobacteriaceae and Pseudomonas aeruginosa Isolated by Clinical Laboratories in 40 Countries from 2012 to 2015.

Authors:  James A Karlowsky; Krystyna M Kazmierczak; Boudewijn L M de Jonge; Meredith A Hackel; Daniel F Sahm; Patricia A Bradford
Journal:  Antimicrob Agents Chemother       Date:  2017-08-24       Impact factor: 5.191

5.  Identifying Spectra of Activity and Therapeutic Niches for Ceftazidime-Avibactam and Imipenem-Relebactam against Carbapenem-Resistant Enterobacteriaceae.

Authors:  Ghady Haidar; Cornelius J Clancy; Liang Chen; Palash Samanta; Ryan K Shields; Barry N Kreiswirth; M Hong Nguyen
Journal:  Antimicrob Agents Chemother       Date:  2017-08-24       Impact factor: 5.191

Review 6.  Development of novel antibacterial drugs to combat multiple resistant organisms.

Authors:  Matteo Bassetti; Elda Righi
Journal:  Langenbecks Arch Surg       Date:  2015-02-11       Impact factor: 3.445

7.  Kinetics of avibactam inhibition against Class A, C, and D β-lactamases.

Authors:  David E Ehmann; Haris Jahic; Philip L Ross; Rong-Fang Gu; Jun Hu; Thomas F Durand-Réville; Sushmita Lahiri; Jason Thresher; Stephania Livchak; Ning Gao; Tiffany Palmer; Grant K Walkup; Stewart L Fisher
Journal:  J Biol Chem       Date:  2013-08-02       Impact factor: 5.157

Review 8.  Investigational antimicrobial agents of 2013.

Authors:  Michael J Pucci; Karen Bush
Journal:  Clin Microbiol Rev       Date:  2013-10       Impact factor: 26.132

9.  In vitro activity of ceftazidime-avibactam combination in in vitro checkerboard assays.

Authors:  Johanna Berkhout; Maria J Melchers; Anita C van Mil; Wright W Nichols; Johan W Mouton
Journal:  Antimicrob Agents Chemother       Date:  2014-12-08       Impact factor: 5.191

10.  In Vitro and In Vivo Activities of OP0595, a New Diazabicyclooctane, against CTX-M-15-Positive Escherichia coli and KPC-Positive Klebsiella pneumoniae.

Authors:  Akihiro Morinaka; Yuko Tsutsumi; Keiko Yamada; Yoshihiro Takayama; Shiro Sakakibara; Toshihiko Takata; Takao Abe; Takeshi Furuuchi; Seiichi Inamura; Yoshiaki Sakamaki; Nakako Tsujii; Takashi Ida
Journal:  Antimicrob Agents Chemother       Date:  2016-04-22       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.